The CooperCOO +0.52%89 EPS without NRI is $4.56 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.88 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 666 Medical Devices & Instruments companies, The Cooper ranks better than 52.85% on this metric.
The Cooper's earnings per share without non-recurring items for the
three
months ended in Apr. 2026 was $1.21.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was $4.56.
During the past 12 months, The Cooper's average earnings per share (NRI) Growth Rate was 17.50% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 10.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 9.10% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for The Cooper's EPS without NRI or its related term are showing as below:
COO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.9 Med: 12.65 Max: 178.7
Current: 10
During the past 13 years, The Cooper's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 178.70% per year. The lowest was -53.90% per year. And the median was 12.65% per year.
COO's 3-Year EPS without NRI Growth Rate is ranked better than 52.85% of 666
companies
in the Medical Devices & Instruments industry
Industry Median: 8.15
vs COO: 10.00
The Cooper's EPS (Diluted) for the
three
months ended in Apr. 2026 was $-0.40.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $1.18.
The Cooper's EPS (Basic) for the
three
months ended in Apr. 2026 was $-0.40.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $1.19.
The Cooper (NAS:COO) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
The Cooper EPS without NRI Related Terms
The Cooper EPS without NRI Historical Data
* Premium members only.
The historical data trend for The Cooper's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where The Cooper's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a EPS without NRI of $4.56 as of Apr. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #314 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 47.1%.
Is The Cooper's EPS without NRI too high?
The Cooper's current EPS without NRI is $4.56. The Medical Devices & Instruments industry median EPS without NRI is 8.15. The Cooper's value of $4.56 is 44% below this industry median. Based on the distribution chart, The Cooper ranks #314 out of 666 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's EPS without NRI compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #314 out of 666 companies for EPS without NRI. This puts The Cooper in the upper half of its industry. The industry median EPS without NRI is 8.15. The Cooper's value of $4.56 is 44% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current EPS without NRI of $4.56 is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current EPS without NRI is $4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $71.39 — trading 29.2% below its estimated fair value. The current EPS without NRI is $4.56 and 44% below the Medical Devices & Instruments industry median of 8.15. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For The Cooper (COO), the current EPS without NRI is $4.56 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.39 is trading 29.2% below its estimated GF Value™ of $100.88.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
EPS without NRI: $4.56
GF Value™: $100.88 vs. price of $71.39 (29.2% below fair value)
Industry Position: 44% below the Medical Devices & Instruments median (#314 of 666)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
